Naveen Krishnan
Managing Director at Mirae Asset Capital Life Science
Boston, Massachusetts
Overview
Work Experience
Board Member
2023 - Current
Accent Therapeutics is a biopharmaceutical company.
Raised $178,000,000.00 from Bristol-Myers Squibb, Atlas Venture, NS Investment, Mirae Asset Venture Investment, EcoR1 Capital, Mirae Asset Capital, The Mark Foundation for Cancer Research, Droia Ventures, The Column Group and Mirae Asset Capital Life Science.
SVP & Managing Director
2023
Leading Mirae Asset Financial Group's ($600bn AUM) first U.S.-based venture capital firm dedicated to investing in life science companies
Mirae Asset Capital Life Science is an investment company that provides financial solutions for companies prioritizing life science.
Senior Director of Venture Investment
2020 - 2023
Helped to lead minority equity investments in healthcare across genetic disease/gene therapy, cell therapy, regenerative medicine, oncology, autoimmune disease/inflammation, CNS/mental health, and digital health
Board Member
2022 - 2023
Deep understanding of protein homeostasis and ubiquitin biology to effect protein modulation (e.g. degradation) beginning in CNS.
Lyterian Therapeutics focused on developing new drugs for diseases by using natural mechanisms of protein regulation.
Board Member
2021 - 2023
Leveraging the gut-brain-immune axis to deliver live biotherapeutic products in CNS indications (Epilepsy, ALS)
Bloom Science is a clinical-stage central nervous system company developing novel therapeutics for patients with neurological disorders.
Raised $12,000,000.00 from Joyance Partners, Leaps by Bayer, Apollo Health Ventures and ALS Investment Fund.
Board Member
2021 - 2023
AI-driven chat bot utilizing validated psychiatry/psychology principles (CBT, DBT, IPT) to deliver prescription and non-prescription digital therapeutics for mental health.
Woebot Health provides behavioral health solutions and prescription for adolescent and postpartum depression.
Raised $123,300,000.00 from Leaps by Bayer.
Board Member
2021 - 2023
One of the world's leading health symptom assessment apps revolutionizing the digital healthcare journey for patients.
Board Member
2021 - 2022
Revolutionizing the manufacturing for iPSC-derived cell therapies
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies.
Raised $122,500,002.00 from Advanced Research Projects Agency for Health.
Board Member
2021 - 2022
Developing the first biomarker for systemic chronic inflammation using serum-derived immunological proteins leveraging the data from a 10-year longitudinal study from Stanford (1KIP).
Edifice Health is a immunological health and personalized nutrition company offering a novel metric of inflammatory health.
Raised $13,500,000.00 from Leaps by Bayer.
Board Member
2021 - 2022
Genetic engineering of skin microbes to treat dermatologic conditions with a lead program in Netherton Syndrome. IND for Netherton syndrome cleared by FDA at the end of 2022, IPO in H1 2023 (NYSE: AZTR).
Azitra is a clinical-stage medical dermatology company developing microbiome-based novel therapeutics to treat skin conditions and diseases.
Raised $52,844,700.00 from Connecticut Innovations, Bios Partners and Leaps by Bayer.